Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 12, Issue 1, Pages 42-53Publisher
SPRINGER
DOI: 10.1007/s11910-011-0240-9
Keywords
Spinal muscular atrophy; SMA; SMN1; SMN2; Therapeutics; Clinical trials; Sensory; Motor; AAV9; Gene therapy; Humans; Animal models; Motor neuron; Spinal cord circuitry; Anterior horn cell; Natural history; Outcomes; Phenotype; Review; RNA splicing; Preclinical
Categories
Funding
- National Institute of Health of Child Health and Human Development
- Muscular Dystrophy Association
Ask authors/readers for more resources
Bench to bedside progress has been widely anticipated for a growing number of neurodegenerative disorders. Of these, spinal muscular atrophy (SMA) is perhaps the best poised to capitalize on advances in targeted therapeutics development over the next few years. Several laboratories have achieved compelling success in SMA animal models using sophisticated methods for targeted delivery, repair, or increased expression of the survival motor neuron protein, SMN. The clinical community is actively collaborating to identify, develop, and validate outcome measures and biomarkers in parallel with laboratory efforts. Innovative trial design and synergistic approaches to maximize proactive care in conjunction with treatment with one or more of the promising pharmacologic and biologic therapies currently in the pipeline will maximize our chances to achieve meaningful outcomes for patients. This review highlights recent promising scientific and clinical advances bringing us ever closer to effective treatment(s) for our patients with SMA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available